<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Russian Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский медицинский журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-2106</issn><issn publication-format="electronic">2412-9100</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">643065</article-id><article-id pub-id-type="doi">10.17816/medjrf643065</article-id><article-id pub-id-type="edn">RULQJZ</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Научные обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Association between psoriasis and gut microbiota: a review</article-title><trans-title-group xml:lang="ru"><trans-title>Взаимосвязь псориаза и микробиоты кишечника: обзор литературы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-9292-165X</contrib-id><name-alternatives><name xml:lang="en"><surname>Vasilieva</surname><given-names>Valeria P.</given-names></name><name xml:lang="ru"><surname>Васильева</surname><given-names>Валерия Павловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>valeriavas19@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-2224-2217</contrib-id><name-alternatives><name xml:lang="en"><surname>Yenina</surname><given-names>Daria S.</given-names></name><name xml:lang="ru"><surname>Енина</surname><given-names>Дарья Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>eninad1212@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-3756-6768</contrib-id><name-alternatives><name xml:lang="en"><surname>Kapustina</surname><given-names>Elizaveta I.</given-names></name><name xml:lang="ru"><surname>Капустина</surname><given-names>Елизавета Игоревна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>lizaogneva2002@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-2021-1022</contrib-id><name-alternatives><name xml:lang="en"><surname>Kapko</surname><given-names>Anastasia V.</given-names></name><name xml:lang="ru"><surname>Капко</surname><given-names>Анастасия Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>kapkooo7@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-5166-2297</contrib-id><name-alternatives><name xml:lang="en"><surname>Cherkasova</surname><given-names>Alexandra A.</given-names></name><name xml:lang="ru"><surname>Черкасова</surname><given-names>Александра Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alexandra_cher390@mail.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9939-3443</contrib-id><contrib-id contrib-id-type="spin">9133-3802</contrib-id><name-alternatives><name xml:lang="en"><surname>Raevsky</surname><given-names>Kirill Pavlovich</given-names></name><name xml:lang="ru"><surname>Раевский</surname><given-names>Кирилл Павлович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>raevskiykirill17@gmail.com</email><xref ref-type="aff" rid="aff5"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Saint-Petersburg State Pediatric Medical University</institution></aff><aff><institution xml:lang="ru">Санкт-Петербургский государственный педиатрический медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Academician I.P. Pavlov First St. Petersburg State Medical University</institution></aff><aff><institution xml:lang="ru">Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">University REAVIZ</institution></aff><aff><institution xml:lang="ru">Университет «Реавиз»</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Almazov National Medical Research Centre</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр имени В.А. Алмазова</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">Московский государственный университет имени М.В. Ломоносова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-03-30" publication-format="electronic"><day>30</day><month>03</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-06-11" publication-format="electronic"><day>11</day><month>06</month><year>2025</year></pub-date><volume>31</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>298</fpage><lpage>306</lpage><history><date date-type="received" iso-8601-date="2024-12-15"><day>15</day><month>12</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-03-30"><day>30</day><month>03</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2028-07-11"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://medjrf.com/0869-2106/article/view/643065">https://medjrf.com/0869-2106/article/view/643065</self-uri><abstract xml:lang="en"><p>Psoriasis is a systemic immune-mediated inflammatory disease that affects target organs and manifests primarily through skin lesions resulting from keratinocyte hyperproliferation. This condition can significantly reduce the quality of life. Psoriasis is widespread: according to the scientific data, it affects approximately 2% of the global population. Research in the psoriasis pathogenesis and its systemic effects remains a relevant focus in dermatology. Numerous recent studies have identified a correlation between psoriasis and inflammatory bowel diseases.</p> <p>Psoriasis has been found to reduce both the qualitative and quantitative diversity of the gut microbiota, as well as to increase in opportunistic bacteria such as <italic>Escherichia coli</italic>, <italic>Helicobacter </italic>spp., and <italic>Mycobacterium </italic>spp. In addition, patients with psoriasis exhibit an increased abundance of <italic>Firmicutes </italic>and a decrease in <italic>Bacteroides</italic>. A decrease in <italic>Bacteroides</italic>, in turn, reduces the production of butyrate, which plays a key role in protecting the intestinal epithelium. Alterations in the gut microbiota may contribute to the stimulation of autoimmune inflammation in psoriasis. Many researchers also agree that severe psoriasis is characterized by significantly altered microbiota in the study groups compared with controls. Intestinal dysbiosis may serve as a trigger for psoriasis relapse. Increased intestinal epithelial permeability contributes to the entry of a greater number of bacterial metabolites into the bloodstream, which in turn aggravates the course of psoriasis.</p> <p>Clinical observations confirm the improvement of psoriatic skin lesions following the use of antibiotics, probiotics, or fecal microbiota transplantation. A detailed investigation of the relationship between psoriasis and the gut microbiota may serve as a potential marker for therapy assessment, improve treatment quality, and enhance the quality of life in affected patients.</p></abstract><trans-abstract xml:lang="ru"><p>Псориаз — системное иммуновоспалительное заболевание, поражающее органы-мишени и проявляющееся главным образом образованием дефекта на коже вследствие гиперпролиферации кератиноцитов. Это заболевание может значительно снижать качество жизни. Псориаз распространён повсеместно: по литературным данным, он затрагивает около 2% населения планеты. Изучение патогенеза псориаза и его влияния на организм является актуальным направлением в дерматологии. Многочисленные работы последних лет обнаруживают определённую корреляцию между псориазом и воспалительными заболеваниями кишечника.</p> <p>Установлено, что при псориазе наблюдается снижение качественного и количественного разнообразия микрофлоры кишечника и увеличение числа условно-патогенных бактерий, например <italic>Escherichia coli</italic>, <italic>Helicobacter </italic>spp., <italic>Mycobacterium </italic>spp. Наряду с этим у больных псориазом выявляется увеличение количества бактерий типа <italic>Firmicutes </italic>и снижение — <italic>Bacteroides</italic>. Уменьшение количества <italic>Bacteroides </italic>в свою очередь ведёт к уменьшению образования бутирата, который играет роль в защитной системе эпителия кишечника. Изменение микробиоты кишечника может являться причиной стимуляции аутоиммунного воспаления при псориазе. Многие исследователи также сходятся во мнении, что тяжёлое течение псориаза характеризуется значительно изменённой микробиотой у исследуемых групп по сравнению с контрольными. Дисбиоз кишечника может являться стимулом рецидива псориаза. Повышение проницаемости кишечного эпителия способствует проникновению большего количества бактериальных метаболитов в кровь, что в свою очередь усугубляет течение псориаза.</p> <p>Клинические наблюдения подтверждают улучшение псориатических поражений кожи после применения антибиотиков, пробиотиков или трансплантации фекальной микробиоты. Детальное изучение взаимоотношения псориаза и микробиоты кишечника может служить потенциальным маркером оценки проводимой терапии, улучшать её качество и повышать уровень жизни пациентов с данной патологией.</p></trans-abstract><kwd-group xml:lang="en"><kwd>psoriasis</kwd><kwd>intestinal microbiota</kwd><kwd>inflammatory bowel diseases</kwd><kwd>intestinal dysbiosis</kwd><kwd>immune-mediated inflammatory diseases</kwd><kwd>keratinocyte hyperproliferation</kwd><kwd>immune response</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>псориаз</kwd><kwd>микробиота кишечника</kwd><kwd>воспалительные заболевания кишечника</kwd><kwd>дисбиоз кишечника</kwd><kwd>иммуновоспалительные заболевания</kwd><kwd>гиперпролиферация кератиноцитов</kwd><kwd>иммунный ответ</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Sieminska I, Pieniawska M, Grzywa TM. The immunology of psoriasis-current concepts in pathogenesis. Clin Rev Allergy Immunol. 2024;66(2):164–191. doi: 10.1007/s12016-024-08991-7 EDN: XVPYCN</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Khairutdinov VR, Samtsov AV. Psoriasis: modern concepts of dermatosis. Manual for physicians. Moscow: GEOTAR-Media; 2021. (In Russ.)</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Raznatovsky KI, Dreval RO, Zhukova OV, et al. Assessment of the economic burden and the current state of the drug provision organization for patients with psoriasis in the Russian Federation. Russian Journal of Clinical Dermatology and Venereology. 2021;20(3):8–16. doi: 10.17116/klinderma2021200318 EDN: CRLTOU</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gräna F, Kerstana A, Serfling E, et al. Current developments in the immunology of psoriasis. Yale Journal of Biology and Medicine. 2020;93:97–110.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Askhakov MS, Chebotaryov VV. Psoriasis: the modern idea of dermatosis. Medical News of North Caucasus. 2017;12(2): 225–229. doi: 10.14300/mnnc.2017.12065 EDN: ZCGGTB</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bakulev AL. Clinical features of psoriasis, risk factors and associated comorbidity. Klinicheskaja farmakologija i terapija. 2019;28(1):35–39. doi: 10.32756/0869-5490-2019-1-35-39 EDN: FCQAVV</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012;18(7):1340–1355. doi: 10.1002/ibd.21903</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kaybysheva VO, Zharova ME, Filimendikova KYu, Nikonov EL. Human microbiome: age-related changes and functions. Russian Journal of Evidence-Based Gastroenterology. 2020;9(2):42–55. doi: 10.17116/dokgastro2020902142 EDN: YKXBBQ</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Buhaș MC, Gavrilaș LI, Candrea R, et al. Gut microbiota in psoriasis. Nutrients. 2022;14(14):2970. doi: 10.3390/nu14142970 EDN: VSSVEJ</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Karyakina LA, Kukushkina KS, Karyakin AS. Gastroenterological problems of psoriasis. Children's Medicine of the North-West. 2023;11(1):32–41. doi: 10.56871/CmN-W.2023.72.61.003 EDN: EAHIRF</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Schade L, Mesa D, Faria AR, et al. The gut microbiota profile in psoriasis: a Brazilian case-control study. Lett Appl Microbiol. 2022;74(4):498–504. doi: 10.1111/lam.13630 EDN: CCUUJN</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Nikolaeva AA, Shishkin AN. The features of the gut microbiota in psoriasis and psoriatic arthritis. Zdorov''e — osnova chelovecheskogo potenciala: problemy i puti ih reshenija. 2021;16(2):457–463. EDN: DXYQHJ</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Sikora M, Stec A, Chrabaszcz M, et al. Gut microbiome in psoriasis: an updated review. Pathogens. 2020;9(6):463. doi: 10.3390/pathogens9060463 EDN: RVTAQF</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Wu R, Zhao L, Wu Z, et al. Psoriasis and gut microbiota: A Mendelian randomization study. J Cell Mol Med. 2024;28(1):e18023. doi: 10.1111/jcmm.18023 EDN: IDKSQN</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Thye AY, Bah YR, Law JW, et al. Gut-skin axis: unravelling the connection between the gut microbiome and psoriasis. Biomedicines. 2022;10(5):1037. doi: 10.3390/biomedicines10051037</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kornienko EA. Intestinal microbiota as a key factor in the formation of immunity and tolerance. Probiotics capabilities. Medical Council. 2020;(10):92–100. doi: 10.21518/2079-701X-2020-10-92-100 EDN: BOIHAB</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Kaibysheva VO, Zharova ME, Filimendikova KYu, Nikonov EL. Diseases associated with disturbed intestinal microbiota. Doctor.Ru. 2021;20(4):40–45. doi: 10.31550/1727-2378-2021-20-4-40-45 EDN: ODBQHS</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Goncharov AA, Dolgikh OV. Immunological and genetic features of pathogenetic association between psoriasis and colonic dysbiosis. Russian Journal of Infection and Immunity. 2021;11(2):237–248. doi: 10.15789/2220-7619-IAG-1277 EDN: HGXUAM</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Eppinga H, Sperna Weiland CJ, Thio HB, et al. Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in hidradenitis suppurativa. J Crohns Colitis. 2016;10(9):1067–1075. doi: 10.1093/ecco-jcc/jjw070</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Olejniczak-Staruch I, Ciążyńska M, Sobolewska-Sztychny D, et al. Alterations of the skin and gut microbiome in psoriasis and psoriatic arthritis. Int J Mol Sci. 2021;22(8):3998. doi: 10.3390/ijms22083998 EDN: CDDTJK</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Ermekbayeva BA, Batpenova GR, Algazina TO. University Medical Center Corporate Foundation. Methodical recommendations “Auxiliary method of psoriasis treatment depending on the structure of the intestinal microbiome”. Moscow: Mir nauki; 2020. (In Russ.)</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Hedin CRH, Sonkoly E, Eberhardson M, Ståhle M. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach. J Intern Med. 2021;290(2):257–278. doi: 10.1111/joim.13282 EDN: GQACJK</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Barilo AA, Smirnova SV. The role of nutritional factors and food allergy in the development of psoriasis. Problems of Nutrition. 2020;89(1):19–27. doi: 10.24411/0042-8833-2020-10002 EDN: NKFIRZ</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Manara S, Beghini F, Masetti G, et al. Thermal therapy modulation of the psoriasis-associated skin and gut microbiome. Dermatol Ther (Heidelb). 2023;13(11):2769–2783. doi: 10.1007/s13555-023-01036-5 EDN: NZXTVA</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Sun C, Chen L, Yang H, et al. Involvement of gut microbiota in the development of psoriasis vulgaris. Front Nutr. 2021;8:761978. doi: 10.3389/fnut.2021.761978 EDN: NQFFNW</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Shapiro J, Cohen NA, Shalev V, et al. Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls. J Dermatol. 2019;46(7):595–603. doi: 10.1111/1346-8138.14933</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Dei-Cas I, Giliberto F, Luce L, et al. Metagenomic analysis of gut microbiota in non-treated plaque psoriasis patients stratified by disease severity: development of a new Psoriasis-Microbiome Index. Sci Rep. 2020;10(1):12754. doi: 10.1038/s41598-020-69537-3 EDN: BCLFFA</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Yegorov S, Babenko D, Kozhakhmetov S, et al. Psoriasis is associated with elevated gut IL-1α and intestinal microbiome alterations. Front Immunol. 2020;11:571319. doi: 10.3389/fimmu.2020.571319 EDN: ALKGQN</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Chen HL, Zeng YB, Zhang ZY, et al. Gut and cutaneous microbiome featuring abundance of Lactobacillus reuteri protected against psoriasis-like inflammation in mice. J Inflamm Res. 2021;14:6175–6190. doi: 10.2147/JIR.S337031</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Chen L, Li J, Zhu W, et al. Skin and gut microbiome in psoriasis: gaining insight into the pathophysiology of it and finding novel therapeutic strategies. Front Microbiol. 2020;11:589726. doi: 10.3389/fmicb.2020.589726 EDN: KLALOZ</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Pinget GV, Tan JK, Ni D, et al. Dysbiosis in imiquimod-induced psoriasis alters gut immunity and exacerbates colitis development. Cell Rep. 2022;40(7):111191. doi: 10.1016/j.celrep.2022.111191</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Li XQ, Chen Y, Dai GC, et al. Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. J Ethnopharmacol. 2021;272:113934. doi: 10.1016/j.jep.2021.113934 EDN: HNYNDN</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Zhang X, Shi L, Sun T, et al. Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients. BMC Microbiol. 2021;21(1):78. doi: 10.1186/s12866-021-02125-1 EDN: OJTAQB</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Wen C, Pan Y, Gao M, et al. Altered gut microbiome composition in nontreated plaque psoriasis patients. Microb Pathog. 2023;175:105970. doi: 10.1016/j.micpath.2023.105970 EDN: LJNSHQ</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Du X, Yan C, Kong S, et al. Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes. Front Microbiol. 2023;14:1227309. doi: 10.3389/fmicb.2023.1227309 EDN: YACILO</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Telesford KM, Yan W, Ochoa-Reparaz J, et al. A commensal symbiotic factor derived from Bacteroides fragilis promotes human CD39(+)Foxp3(+) T cells and Treg function. Gut Microbes. 2015;6(4):234–242. doi: 10.1080/19490976.2015.1056973</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Polak K, Bergler-Czop B, Szczepanek M, et al. Psoriasis and gut microbiome-current state of art. Int J Mol Sci. 2021;22(9):4529. doi: 10.3390/ijms22094529 EDN: JJAGVS</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Ko SH, Chi CC, Yeh ML, et al. Lifestyle changes for treating psoriasis. Cochrane Database Syst Rev. 2019;7(7):CD011972. doi: 10.1002/14651858.CD011972.pub2</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Tan L, Zhao S, Zhu W, et al. The Akkermansia muciniphila is a gut microbiota signature in psoriasis. Exp Dermatol. 2018;27(2):144–149. doi: 10.1111/exd.13463</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Esquivel-Elizondo S, Ilhan ZE, Garcia-Peña EI, Krajmalnik-Brown R. Insights into butyrate production in a controlled fermentation system via gene predictions. mSystems. 2017;2(4):e00051–e00017. doi: 10.1128/mSystems.00051-17</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Okada K, Matsushima Y, Mizutani K, Yamanaka K. The role of gut microbiome in psoriasis: oral administration of Staphylococcus aureus and Streptococcus danieliae exacerbates skin inflammation of imiquimod-induced psoriasis-like dermatitis. Int J Mol Sci. 2020;21(9):3303. doi: 10.3390/ijms21093303 EDN: OODNZD</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Kiryanova VV, Raznatovsky KI, Petrova EV, et al. Intestinal microbiota in patients with progressive psoriasis and its dynamics as influenced by photochromotherapy. Vestnik fizioterapii i kurortologii. 2020;26(1):11–17. EDN: KZYOZC</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Buhaș MC, Candrea R, Gavrilaș LI, et al. Transforming psoriasis care: probiotics and prebiotics as novel therapeutic approaches. Int J Mol Sci. 2023;24(13):11225. doi: 10.3390/ijms241311225 EDN: NPSRLQ</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Moludi J, Fathollahi P, Khedmatgozar H, et al. Probiotics supplementation improves quality of life, clinical symptoms, and inflammatory status in patients with psoriasis. J Drugs Dermatol. 2022;21(6):637–644. doi: 10.36849/JDD.6237 EDN: JOLQLA</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Wei K, Liao X, Yang T, et al. Efficacy of probiotic supplementation in the treatment of psoriasis — A systematic review and meta-analysis. J Cosmet Dermatol. 2024;23(7):2361–2367. doi: 10.1111/jocd.16299 EDN: RMRSZR</mixed-citation></ref></ref-list></back></article>
